Abiomed (NSDQ:ABMD) said today it launched the Impella quality assurance program, looking to improve outcomes for cardiogenic shock and protected PCI patients.
The Danvers, Mass.-based company said the program will use data from its IQ Database, which includes observational quality assurance data on over 95% of Impella patients since 2008, including more than 44,000 Impella case entries.
The IQ program will complement best practices alongside Abiomed’s 250-person clinical field team, the company said.
“Abiomed has created the largest high-risk PCI and cardiogenic shock database of real-world evidence with different levels of analysis from observational quality assessment, to IRB prospective registries, to FDA prospective randomized studies. We believe that by sharing our data-driven insights and clinical expertise, we can help hospitals create protocols, processes, and best practices to improve outcomes in Protected PCI and cardiogenic shock around native heart recovery,” prez, chair & CEO Michael Minogue said in a press release.
The program is part of Abiomed’s education and training initiatives, the company said, which has a goal of “positively affecting both survival and recovery outcomes for this very high-risk patient population.” The company said it invested more than $85 million in its collection of real-world data.
Last week, Abiomed saw shares dip after it missed the Street’s expectations for its 2nd quarter, despite touting an FDA IDE win for a trial of its Impella CP heart pump.
The Danvers, Mass.-based company posted profits of $8.9 million, or 21¢ per share, on sales of $103 million for the 3 months ended September 30. That amounts to bottom-line growth of 14.7% on sales growth of 34.8% compared with the same period in 2015.
Earnings per share and revenue were just below consensus on The Street, where analysts expected to see sales of $103 million and earnings per share of 24¢.
